A Long-Term, Multicenter, Double-Blind Study of an Escherichia Coli Extract (OM-89) in Female Patients with Recurrent Urinary Tract Infections

Bauer, H; Alloussi, Schanaz; Egger, Günther; Blümlein, H; Cozma, Gabriel; Schulman, Claude

doi:10.1016/j.eururo.2004.12.009

Cited by 128 publications

(125 citation statements)

References 20 publications

Supporting

Mentioning

110

Contrasting

Unclassified

Order By: Relevance

“…Takva je OM-89/ Uro-Vaxom (OM Pharma, Myerlin, Švajcarska) oralna vakcina koja sadrži proteine 18 vrsta uropatogenih bakterija i za koju je pokazano da smanjuje recidive infekcija. Ipak, ova vakcina je, takođe, bila praćena neželjenim dejstvima, a njena svakodnevna primena često nije bila dosledno sprovođena [41].…”

Section: Imunoaktivna Profilaksa (Vakcine)unclassified

Rekurentne infekcije mokraćnih puteva: antimikrobna i imunoaktivna profilaksa

Djukanović

2015

Biomedicinska istraž.

View full text Add to dashboard Cite

Kratak sadržajInfekcije mokraćnih puteva su najčešće bakterijske vanbolničke infekcije od kojih češće oboljevaju žene, а оko 20% do 35% žena nakon prve ima ponovnu infekciju mokraćnih puteva. Rekurentnom infekcijom mokraćnih puteva se smatra infekcija koje se ponavljala najmanje tri puta u prethodnoj godini. Faktori rizika za rekurentne infekcije mokraćnih puteva su menopauza, pozitivna porodična anamneza o urinarnim infekcijama, seksualna aktivnost, promena seksualnog partnera, korišćenje spermicida, kao i deficit lokalnog imuniteta. U svim slučajevima u kojima se dokaže da se radi o renfekcijama neophodno je da se primene mere profilakse.Profilaksa se može sprovoditi antimikrobnim lekovima i drugim metodama i sredstvima. Antimikrobni lekovi se primenjuju kontinuirano ili postkoitalno u trajanju od godinu dana, a kod motivisanih bolesnica može se primeniti samozapočinjanje antimikrobne terapije pri recidivu infekcije.Ostale ne-antimikrobne mere profilakse obuhvataju vaginalnu primenu estrogena kod žena u postmenopauzi koje nisu na hormonskoj supstitucionoj terapiji estrogenima, vaginalnu primenu laktobacila, imunoprofilaksu, kao i korišćenje produkata brusnice, izbegavanje primene spermicida, izbegavanje kupanja u kadi i penama. Imunoaktivna profilaksa (vakcine) rekurentnih infekcija mokraćnih puteva je uvedena sa ciljem da se stimuliše lokalni imunski odgovor protiv uropatogenih bakterija. Vakcine su sastavljene ili od umrtvljenih uropatogenih bakterija ili od liofilizovanih proteina membrane uropatogenih bakterija. Da bi se prevazišla velika antigenska varijabilnost uropatogenih bakterija i njihovi različiti mehanizmi virulencije, brojna eksprimentalna istraživanja su usmerena ka proizvodnji vakcina protiv pojedinih komponenti virulencije bakterija, kao i vakcina protiv genetski modifikovanih sojeva bakterija.Postojanje brojnih mera profilakse govori o njihovoj nedovoljnoj efikasnosti, a kombinovano i uporno sprovođenje proverenih mera predstavlja, za sada, jedini način za sprečavanje recidiva infekcije.Ključne reči: rekurentne infekcije mokraćnih puteva, profilaksa, vakcine UvodInfekcija mokraćnih puteva je naziv koji označava prodor mikroorganizama u prethodno sterilan mokraćni sistem, njihovo razmnožavanje i održavanje koje izaziva zapaljenje kao odgovor domaćina. One predstavljaju ne samo ozbiljan zdravstveni nego

show abstract

Section: Imunoaktivna Profilaksa (Vakcine)unclassified

Rekurentne infekcije mokraćnih puteva: antimikrobna i imunoaktivna profilaksa

Djukanović

2015

Biomedicinska istraž.

View full text Add to dashboard Cite

show abstract

“…In addition, initial findings from human trials reportedly did not demonstrate efficacy of immunization with the type 1 fimbrial adhesin FimH against UTI. In contrast, oral immunization with lyophilized extracts of whole E. coli strains has been used in Europe to prevent recurrent UTI with some success [26]. Immunization with whole E. coli has certain potential advantages.…”

Section: Introductionmentioning

confidence: 99%

A killed, genetically engineered derivative of a wild-type extraintestinal pathogenic E. coli strain is a vaccine candidate

Russo¹,

Beanan²,

Olson³

et al. 2007

Vaccine

View full text Add to dashboard Cite

Infections due to extraintestinal pathogenic E. coli (ExPEC) result in significant morbidity, mortality and increased healthcare costs. An efficacious vaccine against ExPEC would be desirable. In this report we explore the use of killed-whole E. coli as a vaccine immunogen. Given the diversity of capsule and O-antigens in ExPEC we have hypothesized that alternative targets are viable vaccine candidates. We have also hypothesized that immunization with a genetically engineered strain that is deficient in the capsule and O-antigen will generate a greater immune response against antigens other than the capsular and O-antigen epitopes than a wild-type strain. Lastly, we hypothesize that mucosal immunization with killed E. coli has the potential to generate a significant immune response. In this study we demonstrated that nasal immunization with a formalin-killed ExPEC derivative deficient in capsule and O-antigen results in a significantly greater overall humoral response compared to its wild-type derivative (which demonstrates that capsule and/or the O-antigen impede the development of an optimal humoral immune response) and a significantly greater immune response against non-capsular and O-antigen epitopes. These antibodies also bound to a subset of heterologous ExPEC strains and enhanced neutrophil-mediated bactericidal activity against the homologous and a heterologous strain. Taken together these studies support the concept that formalin-killed genetically engineered ExPEC derivatives are whole cell vaccine candidates to prevent infections due to ExPEC.

show abstract

Section: Immunostimulationmentioning

confidence: 99%

“…Naber et al [49] , indicating that it was more effective than placebo [50,51]. In a large-scale controlled study conducted subsequently in which 453 women took oral Uro-Vaxom Ⓡ for a year, the occurrence of UTI was reduced by 34% [51]. In the trial, participants took Uro-Vaxom Ⓡ once daily for 3 months, discontinued for 3 months, took it again but only for the first 10 days of a month once daily for 3 months, and then discontinued for the next 3 months.…”

Section: Immunostimulationmentioning

confidence: 99%

2017 Guidelines of The Korean Association of Urogenital Tract Infection and Inflammation: Recurrent Urinary Tract Infection

Lee

Choe

et al. 2017

Urogenit Tract Infect

View full text Add to dashboard Cite

Recurrent infection after an acute urinary tract infection (UTI) episode is common in adult women. It is onerous to both the patient and the physician to treat frequent recurrent UTI. Every time when UTI recurs, patients experience lower urinary tract symptoms, fatigue, and limitation in everyday life, while the physician has difficulty in counseling patients with a disease entity whose pathophysiology is less known. Currently, prophylactic treatment for recurrent UTI is limited, is ineffective in most cases, and sometimes accompanies unexpected side effects. In this guideline, we aimed to establish feasible and effective recommendations for the treatment of recurrent UTI in healthy adult women.

show abstract

A Long-Term, Multicenter, Double-Blind Study of an Escherichia Coli Extract (OM-89) in Female Patients with Recurrent Urinary Tract Infections

Cited by 128 publications

References 20 publications

Rekurentne infekcije mokraćnih puteva: antimikrobna i imunoaktivna profilaksa

Rekurentne infekcije mokraćnih puteva: antimikrobna i imunoaktivna profilaksa

A killed, genetically engineered derivative of a wild-type extraintestinal pathogenic E. coli strain is a vaccine candidate

2017 Guidelines of The Korean Association of Urogenital Tract Infection and Inflammation: Recurrent Urinary Tract Infection

Contact Info

Product

Resources

About